Neurocrine Biosciences Releases Data From Phase II Study Of Crinecerfont

(RTTNews) - Neurocrine Biosciences, Inc. (NBIX) Monday announced data from its completed Phase II study of crinecerfont (NBI-74788).

The company said the study showed meaningful reductions in all three key disease hormone markers in adult patients with congenital adrenal hyperplasia (CAH), a genetic disorder affecting the adrenal glands.

Crinecerfont treatment produced meaningful reductions in elevated adrenocorticotropic hormone (ACTH) and 17-hydroxyprogesterone (17-OHP) levels by 54% to 75% at all doses studied, together with a dose-related decrease in androstenedione (A4) levels, ranging from 21% to 64%.

At the highest dose of crinecerfont (100 mg twice daily), 75% of patients showed a response of at least 50% reduction from baseline for each of the three hormone markers at day 14.

Treatment with crinecerfont was well tolerated with a favorable safety profile with no related serious adverse events reported. Adverse events reported in two or more participants included headache, upper respiratory tract infection, fatigue, contusion, insomnia and nausea.